| US 7,456,184 B2 | ||
| Melanocortin receptor-specific compounds | ||
| Shubh D. Sharma, Cranbury, N.J. (US); Yi-Qun Shi, East Brunswick, N.J. (US); Zhijun Wu, Plainsboro, N.J. (US); Ramesh Rajpurohit, Hillsboro, N.J. (US); Annette M. Shadiack, Somerset, N.J. (US); Papireddy Purma, Plainsboro, N.J. (US); and Kevin D. Burris, Washington Crossing, Pa. (US) | ||
| Assigned to Palatin Technologies Inc., Cranbury, N.J. (US) | ||
| Filed on Apr. 30, 2004, as Appl. No. 10/837,519. | ||
| Claims priority of provisional application 60/546393, filed on Feb. 19, 2004. | ||
| Claims priority of provisional application 60/467442, filed on May 01, 2003. | ||
| Prior Publication US 2004/0224957 A1, Nov. 11, 2004 | ||
| Int. Cl. A61K 31/497 (2006.01); C07D 403/02 (2006.01) | ||
| U.S. Cl. 514—254.09 [544/373] | 15 Claims |
1. A compound having the formula of structure I:
![]() wherein
X is CH2;
R1 is -L1-J;
one of R2a and R2b is -L2-W and the remaining of R2a and R2b is hydrogen;
R3 is -L3-Q;
L1 is a linker unit selected from the group consisting of —(CH2)2—, —(CH2)3—, —(CH2)y—C(═O)—, —C(═O)—(CH2)y— and —C(═O)—;
J is a substituted or unsubstituted ring structure selected from the group consisting of
![]() L2 is —(CH2)y—;
W is —NH—C(═NH)—NH2;
L3 is a linker unit selected from the group consisting of —(CH2)y—CH(NR6aR6b)—(CH2)y—, —(CH2)y—C(═O)—CH(NR6aR6b)—(CH2)y—, —(CH2)y—C(═O)—, —(CH2)y—CH(CH3)—C(═O)—, —C(═O)—(CH2)y—C(═O)—, —C(═O)—CH(NR6aR6b)—(CH2)y—, —C(═O)—(CH2)y—, —C(═O)—(CH2)y—CH(NR6aR6b)—, —C(═O)—(CH2)y—CH(NR6aR6b)—(CH2)y—, —C(═O)—(CH2)y—CH(NHR6aR6b)—C(═O)— and —C(═O)—;
R6a and R6b are each hydrogen;
Q is
![]() R5a is a C1 to C6 aliphatic linear or branched chain;
R5b is hydrogen; and
each of R4a and R4b is hydrogen; and
y is at each occurrence independently from 1 to 6, provided that where any linker unit includes two y index values, the total
of such y index values is from 2 to 6.
|